AJCC 6 TH EDITION STAGING OF BREAST CARCINOMA. AJCC NODE STAGING -16 CATEGORIES pNX – 1 option pN0 – 5 options; null,(i-),(i+),(mol-),(mol+) pN1 – 4.

Slides:



Advertisements
Similar presentations
Pimp Session: Breast By James Lee, MD.
Advertisements

TNM staging and prognosis Alexandru Eniu, MD, PhD Medical Oncologist Department of Breast Tumors Cancer Institute Ion Chiricuţă Cluj-Napoca, Romania.
Module 6: Clinical Stage and Grade. Introduction Stage and grade determine prognosis Staging reflects the clinical extent of the tumor Grading a tumor.
Breast Cancer. Introduction Most common female cancer Accounts for 32% of all female cancer 211,300 new cases yearly and rising 40,000 deaths yearly.
AJCC Staging Moments AJCC TNM Staging 7th Edition Rectal Case #3 Contributors: J. Milburn Jessup, MD Cancer Diagnosis Program, DCTD, NCI, Rockville, Maryland.
AJCC TNM Staging 7th Edition Thyroid Case #3
AJCC TNM Staging 7th Edition Colon Case #1
Breast Cancer in Pregnancy
AJCC Staging Moments AJCC TNM Staging 7th Edition Melanoma Case #1 Contributors: Jeffrey E. Gershenwald, MD University of Texas MD Anderson Cancer Center,
Breast Pathology Helge Stalsberg MD University Hospital of North Norway.
AJCC Staging Moments AJCC TNM Staging 7th Edition Glottic Larynx Case #1 Contributors: Jatin P. Shah, MD Memorial Sloan-Kettering Cancer Center, New York,
Sentinel Lymph Node procedure Intraoperative Examination Belgian Breast Meeting 14/10/2006 Daniel Faverly MD Pathology Laboratory CMP-LabPatho Centre Communautaire.
National Program of Cancer Registries Education and Training Series How to Collect High Quality Cancer Surveillance Data.
Credit line: Breast. In: Greene, F.L., Compton, C.C., Fritz, A.G., et al., editors. AJCC Cancer Staging Atlas. New York: Springer, 2006: ©American.
Histopathology and staging of breast cancer
Malignant Adenomyoepithelioma of the Breast with Lymph Node Metastasis
S ENTINEL L YMPH N ODE M ICROMETASTASIS IN B REAST C ANCER Anthony Fong Yan Chai Hospital.
Sentinel Lymph Node Dissection (SND)
AJCC TNM Staging 7th Edition Breast Case #3
Radiotherapy in Carcinoma of the Breast Patrick S Swift, MD Director, Radiation Oncology Alta Bates Comprehensive Cancer Center Berkeley, CA.
AJCC Staging Moments AJCC TNM Staging 7th Edition Lung Case #3 Contributors: Valerie W. Rusch, MD Memorial Sloan-Kettering Cancer Center, New York, New.
Ductal Carcinoma in situ
BREAST CANCER PROF.NAZEM SHAMS. IS IT A SERIOUS PROBLEM ??
BREAST CANCER.
© Copyright 2003 Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. PET in Breast Cancer Early detection of disease Precise Staging.
AJCC TNM Staging 7th Edition Melanoma Case #2
AJCC Staging Moments AJCC TNM Staging 7th Edition Melanoma Case #3 Contributors: Jeffrey E. Gershenwald, MD University of Texas MD Anderson Cancer Center,
AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #2 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.
AJCC Staging Moments AJCC TNM Staging 7th Edition Colon Case #2 Contributors: J. Milburn Jessup, MD Cancer Diagnosis Program, DCTD, NCI, Rockville, Maryland.
AJCC Staging Moments AJCC TNM Staging 7th Edition Lung Case #1 Contributors: Valerie W. Rusch, MD Memorial Sloan-Kettering Cancer Center, New York, New.
Elshami M.Elamin, MD Medical Oncologist Central Care Cancer Center Wichita, KS, USA
Case Study 63: Cancer of the Female Breast
Aaron Scholnik, M.D., P.K. Pathak, Ph.D., Principal Investigators John McPhail, (Project Manager), Renu Pandit, M.D., Asif Masood, M.D., Department of.
AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #1 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.
SYB Case 2 By: Amy. History 63 y/o female History of left breast infiltrating duct carcinoma s/p mastectomy in 1996 and chemotherapy ER negative, PR negative,
Breast Carcinoma. Anatomy Epidemiology: 10% 17.1/10 28/10 46/ m world wide 6% develop cancer of the breast in their lifetime. 50,000 to 70,000.
Putting the Puzzle Together: Breast Collaborative Staging Melissa Riddle, RHIT, CTR October 6, 2012.
AJCC Staging Moments AJCC TNM Staging 7th Edition Supraglottic Larynx Case #2 Contributors: Jatin P. Shah, MD Memorial Sloan-Kettering Cancer Center, New.
 General recommendations -adjuvant systemic therapy :with tamoxifen or multiple-chemotherapy agent :lower the incidence of recurrence by about 30% - in.
Case 48 y.o. healthy woman Right breast mass present for 4 weeks No other known health problems Clinical breast examination: –Fullness visible in R breast.
EVALUATION OF LYMPH NODES & PATHOLOGIC EXAMINATION FOR BREAST CASES Tonya Brandenburg, MHA, CTR Kentucky Cancer Registry.
Directly Coded Summary Stage Breast Cancer National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention and Control,
The Breast Clinic Index case Year 2 Michaelmas term.
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain.
TREATMENT Mastectomy -traditionally, treatment of breast ca has been surgical -19 century, surgical treatment : local excision ~ total mastectomy : radical.
Lisa Mifsud. Assessment and Management of Surgical Breast Disease.
Colon Cancer. Multihit Concept Clinical Information Clinical Information 1. Patient identification a. Name b. Identification number c. Age (birth date)
TNM Staging: Prostate TONYA BRANDENBURG, MHA, CTR KENTUCKY CANCER REGISTRY.
TNM Staging: Breast TONYA BRANDENBURG, MHA, CTR KENTUCKY CANCER REGISTRY.
Radiotherapy Protocols Bristol protocol version 12.
Pathology.
Tonya Brandenburg, MHA, CTR Kentucky Cancer Registry
Breast Cancer Dr. Gehan Mohamed. Introduction Most common female cancer. The incidence of breast cancer increases with age. 80% of cases occur in post-menopausal.
Breast Anatomic sites and subsites of the breast. Compton, C.C., Byrd, D.R., et al., Editors. AJCC CancerStaging Atlas, 2nd Edition. New York: Springer,
Collaborative Staging for Colon Site Specific Factors Tonya Brandenburg, MHA, CTR QA Manager Abstracting and Coding Kentucky Cancer Registry.
KCR Spring Training T,N,M Case Examples Tonya Brandenburg.
Electronic CAP Cancer Checklists and Cancer Registries – A Pilot Project 2009 NAACCR Conference Ken Gerlach, MPH, CTR Castine Verrill, MS, CTR CDC-National.
PATHOLOGY OF NECK DISSECTION. VIEW FROM DEEP ASPECT OF NECK DISSECTION.
Figure 1: a 32-year-old woman presented with RT breast mass, MRI showed false positive diagnosis of cancer. Dynamic contrast enhanced MRI, axial subtraction.
Cancer: Staging and Grading What is meant by the term “biopsy”? How do tumors behave differently from one another ? Examples of the stages of cancer and.
What is Breast Cancer ? Abnormal cells develop from normal cells in the breast to form tumors Abnormal cells develop from normal cells in the breast to.
Case 3 Jane McNicholas Consultant Oncoplastic Breast Surgeon
Advanced loco regional Regional breast cancer
The IASLC Lung Cancer Staging Project The 8th Edition
CAMELYON17: Moving the challenge to patient level
Basile Pache, Antonia Digklia*, Nicolas Demartines, Maurice Matter.
徐慧萍1 羅竹君1,2 郭耀隆1 李國鼎1 國立成功大學醫學院附設醫院外科部1 國立成功大學醫學院臨床醫學研究所2
What’s New for 8th Edition
TNM 8 UPDATE Head and Neck SSG March 2018
Changes in TNM 8 To be used from
Presentation transcript:

AJCC 6 TH EDITION STAGING OF BREAST CARCINOMA.

AJCC NODE STAGING -16 CATEGORIES pNX – 1 option pN0 – 5 options; null,(i-),(i+),(mol-),(mol+) pN1 – 4 options; mi,a,b,c pN options; a,b,c pN3 – 3 options; a,b,c

5 YR SURVIVAL OF 20,547 WOMEN WITH RESPECT TO LYMPH NODE INVOLVEMENT Cancer 45: , 1980.

N0 N1 N2 N >10

MORE THAN JUST AXILLA 1 - LOW AXILLARY 2 - MID AXILLARY 3 - HIGH AXILLARY (INFRACLAVICULAR) 4 - SUPRACLAVICULAR 5 - INTERNAL MAMMARY 6 – LOW CERVICAL 6

NEGATIVE NODE STAGING pNX – status unknown pN0 – H&E “negative” for carcinoma pN0 (i+ or i-) – H&E “negative” and IPOX stains ordered pN0 (mol+ or mol) – H&E “negative” and RT-PCR ordered “NEGATIVE” = Isolated tumor cells = pN0

DEFINITION –ISOLATED TUMOR CELLS (ITC) Single tumor cells or small clusters of tumor cells which do not aggregate to greater than 0.2 mm and which show no evidence of “proliferation or stromal reaction” Clinical significance unknown (i+) and (i-) (mol+) and (mol-)

ISOLATED TUMOR CELLS pN0(i+) and pN0(mol +) and pN0 (H&E pos for ITC) are not counted as positive nodes eg 0.8 cm tumor with 12 nodes of which 3 “positive by IPOX” only pT1b pN0 pMX Thus “positive” by IPOX but not by N code.

LOW NODE STAGE pN1a 1-3 nodes positive In zones 1 and 2

DEFINITION OF CLINICALLY APPARENT Detected by imaging studies (excluding lymphoscintigraphy) Detected by physical exam Note: No mention of matting of nodes though physical exam detection could represent matting.

Pathologist’s Decision Tree H&E NEGATIVE NO FURTHER STUDY pN0 IPOX STUDY pN0 (i+ or i-) RT-PCR pN0 (mol+ or mol-)

LOW NODE STAGE pN1b not clinically apparent but microscopically detected met

LOW NODE STAGE pN1c 1-3 axillary nodes pos & internal mam. Nodes pos. but not clinically apparent

INTERMEDIATE NODE STAGE pN2a 4-9 axillary nodes pos. with at least one node met > 2 mm

INTERMEDIATE NODE STAGE pN2b clinical apparent int. mammary node, no positive axillary nodes

HIGH STAGE NODE STAGING pN3a Two categories of pN3a - axillary only displayed to the left

HIGH STAGE NODE STAGING pN3a Infraclavicular nodes positive -Second type of pN3a displayed to the left

HIGH STAGE NODE STAGING pN3b Category One - metastasis in clinically apparent Int mammary node plus 1 or more axillary nodes

HIGH STAGE NODE STAGING pN3b Second type - 3 or more axillary nodes + with int. mam. node positive by microscopy only

HIGH STAGE NODE STAGING pN3c Ipsilateral supra- clavicular node met.

WHAT NODE FINDINGS NO LONGER CHANGE STAGING? MACROSCOPIC - MATTING OF NODES MICROSCOPIC – EXTRACAPSULAR EXTENSION OF TUMOR Both of the above are no longer included in the MSP approved synoptic report format.

SENTINEL NODE CLASSIFICATION Sentinel node without accompanying axillary dissection: (sn) e.g. – pN1 (sn); pN0 (i+) (sn) Sentinel node with accompanying axillary dissection: e.g.– pN1; pN0 (i+)

AGGREGATE WITHIN A NODE? Node has no mass greater than 0.2 mm but has multiple masses. What’s the N code? Node has no mass > 0.2 but < 2.0 mm but has multiple masses. What’s the N code. I don’t know the answer but it doesn’t happen very often.

AGGREGATE OR NOT TO AGGREGATE, THAT IS THE ? Each tumor nodule is 0.15 mm. Each is < 0.2 mm When aggregated the sum is 0.45 cm pN0 or pN1mic ?

INTERNAL MAMMARY NODES pN1b - IMN by sentinel node biopsy - mic + by path but not clinically apparent pN1c – axillary nodes plus IMN mic + by path pN2b – clinically apparent IMN with neg. axillary nodes pN3b – IMN clinically apparent with any + axillary nodes

INFRA AND SUPRACLAVICULAR LYMPH NODES pN3a – infraclavicular node positive or >10 axillary nodes with one met > 2 mm pN3c – ipsilateral supraclavicular node positive

GRADING OF TUMORS GX – CANNOT BE ASSESSED G1 – LOW COMBINED HISTOLOGIC GRADE (FAVORABLE) G2 – INTERMEDIATE COMBINED HISTOLOGIC GRADE (MODERATELY FAVORABLE) G3 – HIGH COMBINED HISTOLOGIC GRADE (UNFAVORABLE)

GRADING SYSTEMS IN USE Scarff-Bloom-Richardson -1,2,3 Nottingham ( Elston-Ellis modification of the Scarff-Bloom-Richardson ) – 3 to 9 - based on 1,831 pts - prognosis correlation p < can be applied to most histologic tumor variants (e.g. - not medullary ca)

CAP AND AJCC RECOMMEDED METHOD FOR TUMOR GRADING Nottingham Combined Histologic Score - Tubule Formation (1,2 or 3) - Nuclear Pleomorphism (1,2,or 3) - Mitotic Count (1,2, or 3) Sum T + N + M = Combined Score Score 3-5 = grade 1 Score 6-7 = grade 2 Score 8-9 = grade 3

TUMOR STAGING 18 CATEGORIES – CLINICAL AND PATHOLOGY STAGING THE SAME pTX (eg – gross tumor at margin of resection) pT0 no tumor pTis (DCIS, LCIS, Paget’s) pT1 (a,b,c) 0.1 cm to 2.0 cm pT2 > 2.0 < 5.0 cm pT3 >5.0 cm pT4 (a,b,c,d) chest wall or skin spread

What about invasion < 0.1cm? Termed microinvasion. No T category reserved. Lumped under pT1 as pT1mic Number and size of microinvasive sites should be listed by recommendation of AJCC

WHAT ABOUT COMBINED INSITU AND INVASIVE LESIONS? The staging is by size of only the invasive component. e.g. – 2.5 cm macroscopic tumor mass shows 60% DCIS. Staging is not pT2 (>2 cm) but pT1b or pT1c (0.5 to 2.0 cm).

WHAT ABOUT NEOADJAVANT PRESURGERY CHEMOTHERAPY? All TNM in such case should be preceded by the prefix “y” e.g. – ypT1a

WHAT ABOUT S/P NEEDLE CORE BIOPSIED LESIONS? MEASURE RESIDUAL TUMOR AGGREGATE MEASUREMENT FROM PREVIOUS CORE AND PRESENT LUMPECTOMY / MASTECTOMY e.g. – mammatome biopsy of 0.7 cm and lumpectomy of 0.8 = 1.5 cm or pT1b (if the mammatome biopsy is from the center of the breast mass then aggregating may not be appropriate).

WHAT ABOUT SYNCHRONOUS LESIONS? Largest mass’ measurement provides T Smaller tumor does not get assigned a T Lesions in the same quadrant are not considered synchronous lesions but are “satellite breast nodules” (no change in T) Synchronous bilateral lesions are staged separately.

METASTATIC STAGING pMX - unknown pM0 – no known mets pM1 – distant mets low cervical nodes pectoralis muscle invasion distant organs malignant effusions (supraclavicular nodes no longer > M1)

WHAT IS THE PATHOLOGIST’S RESPONSIBILITY? Use a template that has all the required data fields. Complete the TNM staging at the time of report signing. Use all available resources, reports, history to accurately provide the TNM staging.